ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Therapeutic potential of alpha-pinene in methotrexate-induced testicular toxicity: focus on apoptosis, oxidative stress, and inflammatory pathways.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeMethotrexate (MTX), a widely used chemotherapeutic agent, induces testicular toxicity via oxidative stress, inflammation, and apoptosis. This study aimed to investigate the protective effects of alpha-pinene (APN) against MTX-induced testicular damage in male rats.
methodsAnimals were divided into four groups: vehicle control (VHC), toxicity group (MTX), APN treatment group (APN), and combined group (APN + MTX). Key assessments included body weight changes (BWCs), relative testis weight (RTW), epididymal sperm count (ESC), sperm motility and viability, histopathology, oxidative stress index (OSI), mRNA expression levels of Nrf2, Keap1, and Hmox1, inflammatory cytokines (TNF-α, IL-1, IL-6, and IL-10), and apoptotic markers (Caspase 3 and the BAX/BCL-2 ratio).
resultsMTX significantly reduced BWC (d = -1.84), RTW (d = -3.00), ESC (d = -3.08), sperm motility (d = -7.53), and viability (d = -3.37) while increasing OSI (d = 2.21), TNF-α (d = 2.31), IL-1 (d = 1.97), Caspase 3 (d = 2.43), and BAX/BCL-2 (d = 2.68) (p < 0.05). APN preserved testicular structure and reduced OSI (d = 2.14), TNF-α (d = 2.12), and IL-1 (d = 2.72). Nrf2 expression increased with APN (vs. MTX, d = 1.35), while IL-6, IL-10, and Hmox1 remained statistically unchanged (p > 0.05), despite a large effect size for Hmox1 (d = 1.49).
conclusionAPN attenuated MTX-induced testicular damage by reducing oxidative stress, inflammation, and apoptosis. The unchanged IL-6 and IL-10 levels suggest that APN preserves MTX's immunomodulatory effects while offering protection against fertility impairment.
Indexed as
Identifiers
40632157What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.